Insider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 11,674 Shares of Stock

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $14.12, for a total value of $164,836.88. Following the sale, the insider now owns 3,418,349 shares in the company, valued at $48,267,087.88. This represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total value of $216,090.61.

Abrdn Life Sciences Investors Trading Down 1.4 %

Abrdn Life Sciences Investors stock traded down $0.21 during mid-day trading on Monday, hitting $14.01. The company had a trading volume of 170,163 shares, compared to its average volume of 115,255. The stock's 50 day moving average price is $13.77 and its two-hundred day moving average price is $14.59. Abrdn Life Sciences Investors has a 12 month low of $12.76 and a 12 month high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Thursday, November 21st were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 14.28%. This is an increase from Abrdn Life Sciences Investors's previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HQL. Penserra Capital Management LLC bought a new position in shares of Abrdn Life Sciences Investors during the third quarter valued at $11,702,000. Absolute Investment Advisers LLC bought a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at $5,242,000. Wolverine Asset Management LLC bought a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at $1,594,000. International Assets Investment Management LLC purchased a new stake in Abrdn Life Sciences Investors during the third quarter valued at $204,000. Finally, Kingswood Wealth Advisors LLC purchased a new stake in Abrdn Life Sciences Investors during the fourth quarter valued at $160,000. 32.21% of the stock is owned by institutional investors.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.